GÖTTINGEN, Germany,
Feb. 8, 2022 /PRNewswire/ -- The life
science group Sartorius announced today that, through its subgroup
Sartorius Stedim Biotech, it closed the acquisition of the
Novasep chromatography division as of February 7, 2022, following approval by the U.S.
Federal Trade Commission. The transaction had already been agreed
upon at the beginning of 2021. The business acquired generated
sales of around 40 million euros in
2020 at a double-digit profit margin; final figures for 2021 are
not yet available. The majority of the approximately 100 employees
work at the Pompey site in eastern France and some in the USA, China,
and India.
The portfolio acquired comprises chromatography systems
primarily suited for smaller biomolecules, such as
oligonucleotides, peptides, and insulin, as well as innovative
systems for continuous manufacturing of biologics. Since 2018,
Novasep and Sartorius have also been jointly developing optimized
systems for a membrane-based chromatography technology.
As the acquisition is expected to generate additional
non-organic sales revenue growth of around 1 percentage point
in 2022, Sartorius has updated its sales revenue forecast for the
current year as follows: Consolidated sales revenue is now expected
to increase by about 15 percent to 19 percent (previously about 14
percent to 18 percent), with non-organic growth from acquisitions
projected to contribute about 2 percentage points (previously about
1 percentage point). The company's underlying EBITDA margin remains
forecasted at about 34 percent this year.
For the Bioprocess Solutions Division, the company now forecasts
sales revenue growth of about 17 percent to 21 percent for 2022
(previously about 16 percent to 20 percent), with non-organic
growth from acquisitions contributing around 2 percentage points
(previously around 1 percentage point). The division's underlying
EBITDA margin is still expected to be around 36 percent. The 2022
forecasts for the Lab Products & Services Division remain
unchanged: Accordingly, the company continues to project sales
revenue growth of about 6 percent to 10 percent, including a
non-organic growth contribution from acquisitions of around 1
percentage point, and an underlying EBITDA margin of around 26
percent for the division.
All forecasts are based on constant currencies.
This press release contains forward-looking statements about the
future development of the Sartorius Group. Forward-looking
statements are subject to known and unknown risks, uncertainties
and other factors that could cause actual results to differ
materially from those expressed or implied by such statements.
Sartorius assumes no liability for updating such statements in
light of new information or future events. This is a translation of
the original German-language press release. Sartorius shall not
assume any liability for the correctness of this translation. The
original German press release is the legally binding version.
About Sartorius
The Sartorius Group is a leading
international partner of life science research and the
biopharmaceutical industry. With innovative laboratory instruments
and consumables, the Group's Lab Products & Services Division
concentrates on serving the needs of laboratories performing
research and quality control at pharma and biopharma companies and
those of academic research institutes. The Bioprocess Solutions
Division with its broad product portfolio focusing on single-use
solutions helps customers to manufacture biotech medications and
vaccines safely and efficiently. The Group has been annually
growing by double digits on average and has been regularly
expanding its portfolio by acquisitions of complementary
technologies. In fiscal 2021, the company earned sales revenue of
some 3.45 billion euros according to
preliminary figures. At the end of 2021, nearly 14,000 people were
employed at the Group's approximately 60 manufacturing and sales
sites, serving customers around the globe. Follow Sartorius
on Twitter @Sartorius_Group and on LinkedIn.
Logo:
https://mma.prnewswire.com/media/1123369/Sartorius_Logo.jpg
Contact
Petra
Kirchhoff
Head of Corporate Communications and Investor Relations
+49 (0)551.308.1686
petra.kirchhoff@sartorius.com
www.sartorius.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/sartorius-completes-acquisition-of-novaseps-chromatography-division-301477013.html
SOURCE SARTORIUS CORPORATE ADMINISTRATION GMBH
